This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human RAGE / AGER Protein, Fc Tag
catalog :
AGR-H5253
quantity :
100 ug, 1 mg
price :
250 USD, 1500 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
AGR-H5253
product name :
Human RAGE / AGER Protein, Fc Tag
quantity :
100 ug, 1 mg
price :
250 USD, 1500 USD
quantity & price :
$250/100ug,$1500/1mg (500ug × 2)
target :
RAGE
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
Human RAGE, Fc Tag (AGR-H5253) is expressed from human 293 cells (HEK293). It contains AA Ala 23 - Ala 344 (Accession # NP_001127).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>60% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human RAGE, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 60%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.
References :
(1) Fang F., et al., 2010, FASEB J. 24:1043-1055
(2) Jin Q., et al., 2011, PLoS ONE 6:E19375-E19375
(3) Xue J., et al., 2011, Structure 19:722-732
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments